Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952359 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29403438 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30256684 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30256282 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL540156 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10492407 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30350351 | 0.90 | P2RY2 (0.39) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL20427395 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL800372 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13134626 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136120-A1 | INDUCTION OF IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-05-18 | — | — | US | claimed |
| US-20160051665-A1 | INDUCTION OF IMMUNE RESPONSE | DREXEL UNIVERSITY | 2016-02-25 | — | — | US | claimed |
| US-20130142827-A1 | INDUCTION OF IMMUNE RESPONSE | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A (US) | 2013-06-06 | — | — | US | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20170136120-A1 | INDUCTION OF IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-05-18 | — | — | US | disclosed |
| US-20160051665-A1 | INDUCTION OF IMMUNE RESPONSE | DREXEL UNIVERSITY | 2016-02-25 | — | — | US | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130142827-A1 | INDUCTION OF IMMUNE RESPONSE | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A (US) | 2013-06-06 | — | — | US | disclosed |
| US-8426606-B2 | 2′,2-bisthiazole non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20130059895-A1 | 2',2-DITHIAZOL NON-NUCLEOSIDE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-03-07 | — | — | US | disclosed |
| EP-2551266-A1 | 2',2-DITHIAZOL NON-NUCLEOSIDE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS THEREOF | Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) | 2013-01-30 | — | — | EP | disclosed |
| EP-2517709-A1 | MEDICAL AND PHARMACEUTICAL USE OF 2', 2-BIS-THIAZOLE NON-NUCLEOSIDE COMPOUNDS AS HEPATITIS C VIRUS INHIBITOR | Shanghai Institute of Materia Medica (CN) | 2012-10-31 | — | — | EP | disclosed |
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050080034-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS AG (CH) | 2005-04-14 | — | — | US | disclosed |
| US-20050053625-A1 | Method of treating viral infections | BLOCK TIMOTHY M (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050004357-A1 | Industrially scalable nucleoside synthesis | NOVARTIS AG (CH) | 2005-01-06 | — | — | US | disclosed |
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | DUT, DAO, DCTD | P2RY2 2384/4885P2RY4 2544/4885SLC28A1 188/4885 |
| US-20050004357-A1 | Industrially scalable nucleoside synthesis | ADA, DCTD, PNP | P2RY2 1134/4885P2RY4 1132/4885SLC28A1 22/4885 |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | SLC28A2, SLC28A1, SLC29A2 | P2RY2 800/4885P2RY4 1700/4885SLC28A1 2/4885 |
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | IFNG, OAT, EIF2AK2 | P2RY2 4665/4885P2RY4 4403/4885SLC28A1 110/4885 |
| US-20050080034-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | SLC28A2, SLC28A1, SLC29A2 | P2RY2 800/4885P2RY4 1700/4885SLC28A1 2/4885 |
| US-20130059895-A1 | 2',2-DITHIAZOL NON-NUCLEOSIDE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS THEREOF | SLC29A2, HAVCR2, SLC29A1 | P2RY2 970/4885P2RY4 2086/4885SLC28A1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.